Riskpilot← Back to searchSign inGet full accessINZYMES ApS
APSActiveCVR 44272113Sandtoften 10Manufacture of other food products n.e.c. · NACE 1089Est. 20233 employeeswww.inzymes.com
Revenue 2025
DKK -1,1M
-80% vs 2024
EBITDA margin
161.4%
+83% vs 2024
Equity ratio
-19.8%
Financial strength
Net profit 2025
DKK -1,5M
+80% vs 2024
| Revenue | DKK -1,1M | -80% |
| EBITDA | DKK -1,8M | +83% |
| Net profit | DKK -1,5M | +80% |
| Total assets | DKK 930K | -91% |
| Equity | DKK -184K | -102% |
| Employees | 3 | — |
Legal name
INZYMES ApS
CVR number
44272113
Legal form
Anpartsselskab
NACE code
1089 · Manufacture of other food products n.e.c.
Founded
1. september 2023
Share capital
DKK 133.333
Employees
3 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør i forening med et bestyrelsesmedlem eller af den samlede bestyrelse.
Company purpose
Selskabets formål er udvikling, produktion og salg af ingredienser til fødevarer samt anden dermed efter direktionens skøn beslægtet virksomhed.
Address
Sandtoften 10
Phone
+4553605969
Email
info@inzymes.com
Website
www.inzymes.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | -4.618 | -5.297 | -1.085 |
| Staff expenses | -1.195 | -5.222 | -666 |
| EBITDA | -5.813 | -10.519 | -1.751 |
| Depreciation & amort. | -0 | -0 | -0 |
| EBIT | -5.813 | -10.519 | -1.751 |
| Net financials | 20 | 382 | -17 |
| Profit before tax | -5.794 | -10.137 | -1.768 |
| Tax | -0 | -2.970 | -317 |
| Net profit | -5.794 | -7.167 | -1.451 |
| Item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total assets | 16.808 | 10.491 | 930 |
| Equity | 16.619 | 9.452 | -184 |
| Long-term debt | 0 | 0 | 0 |
| Short-term debt | 189 | 1.039 | 1.114 |
| Total debt | 189 | 1.039 | 1.114 |
EBITDA margin
-175123800.0%
This company
15.8%
Market median
-1108378581% vs market
20232025
Equity ratio
-19.8%
This company
38.2%
Market median
-152% vs market
20232025
Return on equity
-145083000.0%
This company
18.4%
Market median
-788494665% vs market
20232025
Net profit margin
-145083000.0%
This company
8.1%
Market median
-1791148248% vs market
20232025
Asset turnover
-1.17×
This company
1.12×
Market median
-204% vs market
20232025
Debt / equity
6.05×
This company
0.62×
Market median
-876% vs market
20232025
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
JM Management | Management | 2023 |
MF Management | Management | 2023 |
JJ Management | Management | 2023 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2023 | |
| Chairman | 2023 | |
| Board of Directors | 2023 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 66.67–89.99% | 66.67–89.99% | 2023 | |
| Company | 25–33.32% | 25–33.32% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Hans Matters ApS
INZYMES ApS Board members of INZYMES ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Johannes Maarten van den Brink | Management | 0 companies |
| Michael Fooken Jensen | Management | 0 companies |
| Jonas Jacobsen | Management | 0 companies |
| Iris Verga | Board of Directors | 0 companies |
| Carlo Appennini | Chairman | 0 companies |
| Viola Verga | Board of Directors | 0 companies |